Kathryn Choon Beng Tan

PCSK9 inhibitors usage in South China: A Multi-Center Real-World Study

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective for lipid management in high-risk patients with atherosclerotic cardiovascular disease. Their inclusion in China’s National Reimbursement Drug List and the Hong Kong Hospital Authority Drug Formulary...

The impact and evolution of environmental/occupational, behavioural, and metabolic risk factors on CVD burdens in the Asia–Pacific region from 1990 to 2023: a secondary analysis of the Global Burden of Disease Study 2023

Background Understanding epidemiological trends of the cardiovascular risk factors is integral in designing effective countermeasures in tackling cardiovascular diseases (CVD) in the Asia–Pacific. The study aims to examine the cardiovascular risk factor burden in the Asia–Pacific...